Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer

Cancer Medicine

Volumn 4, Issue 9, 2015, Pages 1344-1355

  Kanematsu, Masako ^a   Futamura, Manabu ^a   Takata, Masafumi ^b   Gaowa, Siqin ^a   Yamada, Atsuko ^a   Morimitsu, Kasumi ^a   Morikawa, Akemi ^a   Mori, Ryutaro ^a   Hara, Hideaki ^b   Yoshida, Kazuhiro ^a  

^a GIFU UNIVERSITY   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Breast cancer; Cross talk; GPNMB; HER2

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN NONMETASTATIC B; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GPNMB PROTEIN, HUMAN; PROTEIN BINDING; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BT 474 CELL LINE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURGERY; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MDA MD 157 CELL LINE; MDA MD 231 CELL LINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SK BR 3 CELL LINE; STOMACH CANCER; WESTERN BLOTTING; AGED; BLOOD; BREAST NEOPLASMS; CANCER STAGING; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; MORTALITY; RNA INTERFERENCE; TUMOR CELL LINE;

AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN BINDING; RECEPTOR, ERBB-2; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 85006190120     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.480     Document Type: Article

References (37)

1. Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, et al. 2008. Cancer statistics. CA Cancer J. Clin. 58:71-96.
2. Perou, C. M., T. Sørlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, et al. 2000. Molecular portraits of human breast tumors. Nature 406:747-752.
3. Bartlett, J. M., C. L. Brookes, T. Robson, C. J. van de Velde, L. J. Billingham, F. M. Campbell, et al. 2011. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J. Clin. Oncol. 29:1531-1538.
4. Dawood, S., K. Broglio, A. U. Buzdar, G. N. Hortobagyi, and S. H. Giordano. 2009. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab Treatment: an institutional-based review. J. Clin. Oncol. 28:92-98.
5. Köstler, W. J., B. Schwab, C. F. Singer, R. Neumann, E. Rücklinger, T. Brodowicz, et al. 2004. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin. Cancer Res. 10:1618-1624.
6. Lüftner, D., C. Cheli, K. Mickelson, E. Sampson, and K. Possinger. 2004. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int. J. Biol. Markers 19:175-182.
7. Ludovini, V., S. Gori, M. Colozza, L. Pistola, E. Rulli, I. Floriani, et al. 2008. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann. Oncol. 19:883-890.
8. Hayashi, N., S. Nakamura, Y. Tokuda, H. Yagata, A. Yoshida, H. Ota, et al. 2012. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int. J. Clin. Oncol. 17:55-62.
9. Weterman, M. A., N. Ajubi, I. M. van Dinter, W. G. Degen, G. N. van Muijen, D. J. Ruitter, et al. 1995. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int. J. Cancer 60:73-81.
10. Shikano, S., M. Bonkobara, P. K. Zukas, and K. Ariizumi. 2001. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J. Biol. Chem. 276:8125-8134.
11. Safadi, F. F., J. Xu, S. L. Smock, M. C. Rico, T. A. Owen, and S. N. Popoff. 2001. Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J. Cell. Biochem. 84:12-26.
12. Bandari, P. S., J. Qian, G. Yehia, D. D. Joshi, P. B. Maloof, J. Potian, et al. 2003. Hematopoietic growth factor inducible neurokinin-1 type: a transmembrane protein that is similar to neurokinin 1 interacts with substance P. Requl. Pept. 111:169-178.
13. Tanaka, H., M. Shimazawa, M. Kimura, M. Takata, K. Tsuruma, M. Yamada, et al. 2012. The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Sci. Rep. 2:573-583.
14. Qian, X., E. Mills, M. Torgov, W. J. LaRochelle, and M. Jeffers. 2008. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol. Oncol. 2:81-93.
15. Rose, A. A., A. A. Grosset, Z. Dong, C. Russo, P. A. Macdonald, N. R. Bertos, et al. 2010. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin. Cancer Res. 16:2147-2156.
16. Rho, H. W., B. C. Lee, E. S. Choi, I. I. J. Choi, Y. S. Lee, and S. H. Goh. 2010. Identification of valid reference genes for gene expression studies of human stomach cancer by reverse transcription-qPCR. BMC Cancer 10:240-252.
17. Rose, A. A., F. Pepin, C. Russo, J. E. Abou Khalil, M. Hallett, and P. M. Siegel. 2007. Osteoactivin promotes breast cancer metastasis to bone. Mol. Cancer Res. 5:1001-1014.
18. Kuan, C. T., K. Wakiya, J. M. Dowell, J. E. Herndon II, D. A. Reardon, M. W. Graner, et al. 2006. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin. Cancer Res. 12:1970-1982.
19. Maric, G., A. A. Rose, M. G. Annis, and P. M. Siegel. 2013. Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther. 6:839-852.
20. Rose, A. A., M. G. Annis, Z. Dong, F. Pepin, M. Hallett, M. Park, et al. 2010. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One 5:e12093.
21. Li, Y. N., L. Zhang, X. L. Li, D. J. Cui, H. D. Zheng, S. Y. Yang, et al. 2014. Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancer. APMIS 122:140-146.
22. Futamura, M., H. Kamino, Y. Miyamoto, N. Kitamura, Y. Nakamura, S. Ohnishi, et al. 2007. Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p21.3, in p53-regulated tumor angiogenesis suppression. Cancer Res. 67:1451-1460.
23. Ohnishi, S., M. Futamura, H. Kamino, Y. Nakamura, N. Kitamura, Y. Miyamoto, et al. 2010. Identification of NEEP21, encoding neuron-enriched endosomal protein of 21 kDa, as a transcriptional target of tumor suppressor p53. Int. J. Oncol. 37: 1133-1141.
24. Kanda, Y. 2013. Investigation of the freely available easy-to-use software "EZR" for medical statistics. Bone Marrow Transplant. 48:452-458.
25. Abdelmagid, S. M., M. F. Barbe, M. C. Rico, S. Salihoglu, I. Arango-Hisijara, A. H. Selim, et al. 2008. Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function. Exp. Cell Res. 314:2334-2351.
26. Pegram, M. D., G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon. 2004. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst. 96:739-749.
27. Bendell, J., M. Saleh, A. A. Rose, P. M. Siegel, L. Hart, S. Sirpal, et al. 2014. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 32:3619-3625.
28. Dowsett, M., S. Johnston, L. A. Martin, J. Salter, M. Hills, S. Detre, et al. 2005. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr. Relat. Cancer 12(Suppl. 1):S113-S137.
29. Johnston, S. R. 2010. New strategies in estrogen receptor-positive breast cancer. Clin. Cancer Res. 16:1979-1987.
30. Gijsen, M., P. King, T. Perera, P. J. Parker, A. L. Harris, B. Larijani, et al. 2010. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 Herceptin in breast cancer. PLoS One 12:e1000563.
31. Scaltriti, M., C. Verma, M. Guzman, J. Jimenez, J. L. Parra, K. Pedersen, et al. 2009. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:803-814.
32. Junttila, T. T., R. W. Akita, K. Parsons, C. Fields, G. D. Lewis Phillips, L. S. Friedman, et al. 2009. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440.
33. Gijsen, M., P. King, T. Perera, P. J. Parker, A. L. Harris, B. Larijani, et al. 2010. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 8:e1000563.
34. Lavaud, P., and F. Andre. 2014. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med. 12:132.
35. Cameron, D., M. Casey, C. Oliva, B. Newstat, B. Imwalle, and C. E. Geyer. 2010. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:924-934.
36. Baselga, J., J. Cortés, S. B. Kim, S. A. Im, R. Hegg, Y. H. Im, et al. 2012. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366:109-119.
37. Ott, P. A., O. Hamid, A. C. Pavlick, H. Kluger, K. B. Kim, P. D. Boasberg, et al. 2014. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J. Clin. Oncol. 32:3659-3666.